Drug Fix: What We Learned From The First Medicare Price Negotiation List, Pepaxto Withdrawal Update
Citeline Podcasts
English - September 01, 2023 17:27 - 39 minutes - 23.5 MB - ★★★★★ - 24 ratingsBusiness News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Pink Sheet reporters and editors consider lessons and next steps after the first list of drugs subject to Medicare price negotiations was released (:34) and discuss Oncopeptides’ Pepaxto facing withdrawal under the US FDA’s new and potentially faster process (22:44).
More On The Medicare Price Negotiation List From The Pink Sheet
Litigation Against Medicare Price Negotiation Gains Four Potential New Plaintiffs: https://pink.pharmaintelligence.informa.com/PS148778/Litigation-Against-Medicare-Price-Negotiation-Gains-Four-Potential-New-Plaintiffs
Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data: https://pink.pharmaintelligence.informa.com/PS148781/Medicare-Negotiation-List-Surprises-Highlight-The-Importance-Of-Current-Spending-Data
Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List: https://pink.pharmaintelligence.informa.com/PS148775/Patent-Cliff-Likely-Accelerated-By-Two-Years-For-Most-Drugs-On-Medicare-Price-Negotiation-List
Price Negotiation Purgatory: Upcoming Biosimilars Couldn’t Keep Stelara, NovoLog Off The List: https://pink.pharmaintelligence.informa.com/PS148776/Price-Negotiation-Purgatory-Upcoming-Biosimilars-Couldnt-Keep-Stelara-NovoLog-Off-The-List
Timetable For Medicare Price Negotiation Of The First 10 Drugs (And Beyond): https://pink.pharmaintelligence.informa.com/PS148760/Timetable-For-Medicare-Price-Negotiation-Of-The-First-10-Drugs-And-Beyond
CMS Seeking Patient Comments On Negotiated Drugs Similar To US FDA’s PFDD Program: https://pink.pharmaintelligence.informa.com/PS148773/CMS-Seeking-Patient-Comments-On-Negotiated-Drugs-Similar-To-US-FDAs-PFDD-Program
Big Rebates Already A Big Factor For Drugs On Medicare Negotiation List:
https://pink.pharmaintelligence.informa.com/PS148774/Big-Rebates-Already-A-Big-Factor-For-Drugs-On-Medicare-Negotiation-List
Price Negotiation And The GLP1 Class: Trulicity Lucky To Be A BLA: https://pink.pharmaintelligence.informa.com/PS148794/Price-Negotiation-And-The-GLP1-Class-Trulicity-Lucky-To-Be-A-BLA
More On The Pepaxto Withdrawal From The Pink Sheet
To Save Pepaxto, Oncopeptides Throws Shade At IMiD Use In Elderly Myeloma Patients: https://pink.pharmaintelligence.informa.com/PS148770/To-Save-Pepaxto-Oncopeptides-Throws-Shade-At-IMiD-Use-In-Elderly-Myeloma-Patients
How Fast Is ‘Expedited’? Pepaxto To Show Speed Of New Withdrawal Process For Accelerated Approval Drugs: https://pink.pharmaintelligence.informa.com/PS148766/How-Fast-Is-Expedited-Pepaxto-To-Show-Speed-Of-New-Withdrawal-Process-For-Accelerated-Approval-Drugs
FDA’s Pepaxto Decider: Peter Marks To Handle Oncopeptides’ Appeal Of Accelerated Approval Withdrawal: https://pink.pharmaintelligence.informa.com/PS148761/FDAs-Pepaxto-Decider-Peter-Marks-To-Handle-Oncopeptides-Appeal-Of-Accelerated-Approval-Withdrawal